NESS ZIONA, Israel, April 12,
2018 /PRNewswire/ -- BiondVax Pharmaceuticals
Ltd. (Nasdaq: BVXV), developer of the universal flu vaccine
candidate M-001, reported today it will present at the Universal
Influenza Vaccines 2018 Conference. The conference is being held on
April 16-18 at the University of
Lausanne in Switzerland.
Dr. Tamar Ben-Yedidia,
BiondVax's Chief Science Officer (CSO), will provide an overview of
the Company's clinical development achievements and plans, with a
focus on:
- Results of a Phase 2b trial
conducted in collaboration with the EU-sponsored UNISEC*
consortium
- Update of an ongoing United States NIH-sponsored Phase 2
trial
- Plans for the pivotal, clinical efficacy Phase 3 trial,
expected to begin in 2018
Details of Dr. Ben-Yedidia's talk:
Getting closer to the market: M-001 universal flu vaccine
starting pivotal Phase 3 Trial
Date: Monday, April 16, 2018
Time: 4:00pm (GMT+2)
Location: CHUV, University of Lausanne, Lausanne,
Switzerland
Dr. Ron Babecoff, CEO, and Dr. Ben-Yedidia are serving on the
conference's Scientific Advisory Panel and will be available for
meetings.
* Research supporting UNISEC activities received funding from
the European Union Seventh Framework Programme (FP7/2007-2013)
under grant agreement n°602012.
About BiondVax Pharmaceuticals Ltd
BiondVax is an
advanced clinical stage biopharmaceutical company developing a
universal flu vaccine. The vaccine candidate, called M-001, is
designed to provide multi-season protection against current and
future, seasonal and pandemic influenza virus strains. BiondVax's
proprietary technology utilizes a unique combination of conserved
and common influenza virus peptides, activating both arms of the
immune system for a cross-protecting and long-lasting effect. In a
total of 6 completed Phase 1/2 and Phase 2 human clinical trials,
covering 698 participants, the vaccine has been shown to be safe,
well-tolerated, and immunogenic. BiondVax is traded on NASDAQ:
BVXV. Please visit www.biondvax.com.
Forward Looking Statements
This press release
contains forward-looking statements within the meaning of the
Private Litigation Reform Act of 1995. Words such as "expect,"
"believe," "intend," "plan," "continue," "may," "will,"
"anticipate," and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
involve certain risks and uncertainties reflect the management's
current views with respect to certain current and future events and
are subject to various risks, uncertainties and assumptions that
could cause the results to differ materially from those expected by
the management of BiondVax Pharmaceuticals Ltd. risks and
uncertainties include, but are not limited to, the prosecution and
outcome of the Phase 2 and Phase 3 trials, the risk that drug
development involves a lengthy and expensive process with uncertain
outcome; the ability of the Company to maintain, preserve and
defend its intellectual property and patents granted; whether
our vaccine candidate will successfully advance through the
clinical trial process on a timely basis, or at all, and receive
approval from the United States Food and Drug
Administration or equivalent foreign regulatory agencies; the
adequacy of available cash resource and the ability to raise
capital when needed. More detailed information about the risks
and uncertainties affecting the Company is contained under the
heading "Risk Factors" in our Annual Report on Form 20-F for the
year ended December 31, 2016 filed
with the U.S. Securities and Exchange Commission, or SEC, which is
available on the SEC's website, www.sec.gov, and in the
Company's periodic filings with the SEC and the Tel-Aviv Stock
Exchange.
For further information, please contact:
BiondVax
Joshua
Phillipson
+972-8-930-2529 x5105
j.phillipson@biondvax.com
View original
content:http://www.prnewswire.com/news-releases/biondvax-to-present-at-universal-influenza-vaccines-conference-300628810.html
SOURCE BiondVax Pharmaceuticals Ltd.